Federal Project Grant Award Summary

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Boston Children's Hospital a Project Grant of $167,060 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) for research titled "Defective STAT3 Signaling: Linking Molecular Pathways in VEOIBD Patients to Precision-Based IBD Therapeutic Approaches Targeting IL12/23." The award commenced August 1, 2026, with a completion date of April 30, 2031. The research is being conducted at Boston Children's Hospital in Boston, Massachusetts, a Harvard Medical School-affiliated pediatric teaching hospital and leading federal research institution.

This Project Grant supports basic and clinical biomedical research aimed at understanding the mechanisms underlying very early onset inflammatory bowel disease (VEOIBD) through investigation of defective STAT3 (Signal Transducer and Activator of Transcription 3) signaling pathways in affected patients. The research deliverables are intended to identify molecular mechanisms and translate findings into precision-based therapeutic approaches targeting interleukin-12/23 (IL12/23) signaling, thereby advancing prevention, diagnosis, and treatment strategies for VEOIBD and broader inflammatory bowel disease populations.